1. Home
  2. MCB vs EYPT Comparison

MCB vs EYPT Comparison

Compare MCB & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metropolitan Bank Holding Corp.

MCB

Metropolitan Bank Holding Corp.

HOLD

Current Price

$92.74

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$14.01

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCB
EYPT
Founded
1999
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2017
2005

Fundamental Metrics

Financial Performance
Metric
MCB
EYPT
Price
$92.74
$14.01
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$98.67
$31.80
AVG Volume (30 Days)
140.9K
1.6M
Earning Date
04-21-2026
05-06-2026
Dividend Yield
1.13%
N/A
EPS Growth
11.64
N/A
EPS
4.40
N/A
Revenue
$11,053,000.00
$7,539,000.00
Revenue This Year
$37.22
N/A
Revenue Next Year
$14.75
$3,115.57
P/E Ratio
$21.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$64.66
$9.65
52 Week High
$102.04
$19.11

Technical Indicators

Market Signals
Indicator
MCB
EYPT
Relative Strength Index (RSI) 44.98 50.02
Support Level $86.40 $11.92
Resistance Level $93.56 $13.32
Average True Range (ATR) 2.63 0.82
MACD -0.13 -0.02
Stochastic Oscillator 49.38 57.33

Price Performance

Historical Comparison
MCB
EYPT

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: